BI-3406
98%
- Product Code: 152591
CAS:
2230836-55-0
| Molecular Weight: | 462.473 g./mol | Molecular Formula: | C₂₃H₂₅F₃N₄O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD32197204 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
BI-3406 is a potent and selective inhibitor of the SHP2 phosphatase, a key protein in the RAS/MAPK signaling pathway. It is primarily used in cancer research to target tumors driven by mutations in this pathway, such as those found in certain lung, pancreatic, and colorectal cancers. By inhibiting SHP2, BI-3406 blocks signal transduction that promotes tumor cell growth and survival. It shows strong synergy when combined with MEK inhibitors, enhancing anti-tumor activity in preclinical models. This combination approach helps overcome resistance mechanisms that often limit the effectiveness of single-agent therapies. BI-3406 is therefore a valuable tool in developing combination treatments for RAS-pathway-dependent cancers and is being investigated in early-stage oncology drug development.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 10mg | 10-20 days | ฿3,750.00 |
+
-
|
| 50mg | 10-20 days | ฿11,830.00 |
+
-
|
| 100mg | 10-20 days | ฿18,270.00 |
+
-
|
| 250mg | 10-20 days | ฿28,250.00 |
+
-
|
BI-3406
BI-3406 is a potent and selective inhibitor of the SHP2 phosphatase, a key protein in the RAS/MAPK signaling pathway. It is primarily used in cancer research to target tumors driven by mutations in this pathway, such as those found in certain lung, pancreatic, and colorectal cancers. By inhibiting SHP2, BI-3406 blocks signal transduction that promotes tumor cell growth and survival. It shows strong synergy when combined with MEK inhibitors, enhancing anti-tumor activity in preclinical models. This combination approach helps overcome resistance mechanisms that often limit the effectiveness of single-agent therapies. BI-3406 is therefore a valuable tool in developing combination treatments for RAS-pathway-dependent cancers and is being investigated in early-stage oncology drug development.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :